Company
Dimerix Limited
Headquarters: Fitzroy, VIC, Australia
CEO: Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D.
Market Cap
A$258.6 Million
AUD as of July 1, 2024
US$172.2 Million
Dimerix Limited Categories
Australia Healthcare BiotechnologyAustralia Healthcare Australia Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Dimerix Limited, a clinical-stage biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. The company develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; and DMX-700 that is in pre-clinical development for chronic obstructive pulmonary disease. The company was founded in 2004 and is headquartered in Fitzroy, Australia.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Dimerix Limited has the following listings and related stock indices.
Stock: ASX: DXB wb_incandescent